相关实验视频

Updated: Jul 28, 2025

Optimization of a Quantitative Micro-neutralization Assay

Optimization of a Quantitative Micro-neutralization Assay

Published on: December 14, 2016

在COVID-19的重症患者中使用oseltamivir的效果:一个多中心倾向性得分匹配的研究

Ohoud Aljuhani¹, Ghazwa B Korayem², Ali F Altebainawi^3,4

¹Department of Pharmacy Practice, Faculty of Pharmacy, King Abdulaziz University, Jeddah, Saudi Arabia.

Saudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Society

|May 31, 2023

概括

在重症COVID-19患者中,奥塞尔塔米维尔治疗加速了病毒载荷的清除,减少了机械通风的持续时间. 这项研究发现没有增加安全问题,这表明对严重的COVID-19病例的潜在好处.

科学领域:

关键护理医学关键护理医学
传染病传染病传染病
药理学药理学是指药理学的学科.

背景情况:

奥塞尔塔米维尔用于COVID-19,但对重症患者的证据有限.
严重的COVID-19病例需要有效的辅助疗法.
了解奥塞塔米维尔在重症监护室 (ICU) 设置中的作用至关重要.

研究的目的:

为了评估oseltamivir在重症COVID-19患者中的有效性和安全性.
评估奥塞尔塔米维尔对病毒载荷清除和机械通风持续时间的影响.
确定奥塞塔米维尔是否会影响医院内感染的发生率.

主要方法:

在ICU中的重症成人COVID-19患者的多中心,回顾性队列研究.
根据在ICU入院后48小时内服用oseltamivir的情况,患者被分组为组.
倾向性得分匹配用于比较奥塞尔塔米维尔和对照组,主要终点是病毒载荷清除.

主要成果:

奥塞尔塔米维尔组的病毒载量清除显着更快 (11 vs. 16 天).
在oseltamivir组中观察到更短的机械通风持续时间 (6.5 vs 8.5天).
奥塞塔米维尔的使用与医院/呼吸机获得的肺炎的几率较低有关.

结论:

在重症COVID-19患者中,oseltamivir显示病毒清除速度更快,机械通风持续时间更短.
在30天或住院死亡率方面没有发现显著差异.
奥塞尔塔米维尔似乎是一种安全且潜在的有益的辅助疗法,用于严重的COVID-19.

关键词:

在 COVID-19 疫情中,病情危急,病情危急.在重症监护病房的重症监护病房.机械通风的持续时间死亡率死亡率死亡率奥塞尔塔米维尔 (oseltamivir) 是一种病毒清除时间

更多相关视频

Inverse Probability of Treatment Weighting Propensity Score using the Military Health System Data Repository and National Death Index

Inverse Probability of Treatment Weighting Propensity Score using the Military Health System Data Repository and National Death Index

Published on: January 8, 2020

Biosensor-based High Throughput Biopanning and Bioinformatics Analysis Strategy for the Global Validation of Drug-protein Interactions

Biosensor-based High Throughput Biopanning and Bioinformatics Analysis Strategy for the Global Validation of Drug-protein Interactions

Published on: December 1, 2020

相关概念视频

Acute Respiratory Failure-V

Acute Respiratory Failure-V

The treatment for acute respiratory failure varies based on factors like the underlying cause, overall health, and severity. A collaborative healthcare team is essential for early detection, often through arterial blood gas analysis. Identifying the cause is the primary goal, with treatment strategies adjusted for ventilation/perfusion (V/Q) mismatch, shunting, or diffusion impairment.
Ensure that patients are monitored continuously for their response to therapy, including changes in...

Acute Respiratory Failure-III

Acute Respiratory Failure-III

Hypercapnic respiratory failure, also known as Type 2 or ventilatory respiratory failure, is a severe condition characterized by the body's inability to effectively remove carbon dioxide (CO2) from the bloodstream. It leads to an arterial CO2 pressure (PaCO2) exceeding 45 mmHg and a blood pH above 7.35. This situation indicates that the body's ventilatory demand, or the ventilation needed to maintain normal PaCO2 levels, surpasses its supply or the maximum gas flow achievable without...

Acute Respiratory Failure-II

Acute Respiratory Failure-II

Type I Respiratory Failure, or hypoxemic respiratory failure, occurs when the partial pressure of oxygen (PaO2) in arterial blood falls below 60 mmHg while breathing room air without a corresponding increase in arterial carbon dioxide levels (PaCO2). This condition highlights a significant impairment in the lungs' capacity to oxygenate the blood.
The underlying physiological abnormalities that contribute to hypoxemic respiratory failure include:

Acute Respiratory Failure-IV

Acute Respiratory Failure-IV

Respiratory failure can manifest suddenly or gradually, characterized by a rapid decline in PaO2 and a rapid rise in PaCO2. This situation indicates a severe respiratory problem that may quickly become a life-threatening emergency. One of the early signs of hypoxemic Acute Respiratory Failure (ARF) is a change in mental status due to the brain's sensitivity to oxygen levels and changes in acid-base balance. Symptoms such as restlessness, confusion, and agitation suggest inadequate oxygen...

Acute Respiratory Failure-I

Acute Respiratory Failure-I

Acute respiratory failure is a condition characterized by the inability of the lungs to perform their primary function: gas exchange. This failure leads to insufficient oxygen levels (hypoxemia) in the blood, elevated carbon dioxide levels (hypercapnia), or both, causing critical impairment in organ function.
Definition: It is defined by specific criteria based on blood gas measurements. Hypoxemia happens when the partial pressure of oxygen (PaO2) falls below 60 mmHg. At the same time,...

Pneumonia IV: Management

Pneumonia IV: Management

The treatment of pneumonia varies based on its severity and the causative pathogen. Here is a structured approach to managing pneumonia, integrating pharmaceutical and supportive care strategies.
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include: